<p>隨着美國股市創下新高，標準普爾 500 指數收於歷史最高水平，科技股引領近期漲幅，投資者密切關注高增長行業的潛在機會。在這種環境下，識別強勁的科技股需要考慮它們在不斷變化的經濟條件下的創新能力和韌性。</p>
<h3>美國十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>HubSpot</td>
<td>14.28%</td>
<td>48.34%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Precigen</td>
<td>55.77%</td>
<td>79.70%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器的 73 只股票完整列表。</p>
<p>讓我們深入探討篩選器中的一些優質選擇。</p>
<h2>Viant Technology (DSP)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Viant Technology Inc. 是一家廣告技術公司，市值約為 7.4188 億美元。</p>
<p><strong>運營：</strong> Viant Technology 主要通過其企業技術平台產生收入，該平台貢獻了 3.2413 億美元。公司專注於為客户提供廣告技術解決方案。</p>
<p>Viant Technology 的戰略舉措，包括與 iHeartMedia 的顯著整合以及與 Molson Coors 的合作，突顯了其提升程序化廣告和結果驅動策略的承諾。這從其年收入增長 13.3% 和年盈利增長 44.2% 中可見一斑，均超過美國市場平均水平。公司最近第三季度的銷售額從去年 79.92 百萬美元增加到 85.58 百萬美元，反映出其在競爭激烈的科技領域中成功執行商業模式。Viant 通過直接訪問等舉措專注於與出版商的直接關係，進一步將其定位為連接電視（CTV）和數字廣告領域的創新者，利用先進技術優化廣告支出效率和效果。</p>
<ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 Viant Technology 的動態。</li>
<li>瞭解 Viant Technology 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d76d5b3b-65f9-42ba-b2be-d5bd08db8e8d/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d76d5b3b-65f9-42ba-b2be-d5bd08db8e8d/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 DSP 收入和支出細分</p>
<h2>Dynavax Technologies (DVAX)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Dynavax Technologies Corporation 是一家商業階段的生物製藥公司，專注於在美國和國際上開發和商業化疫苗，市值約為 13.1 億美元。</p>
<p><strong>運營：</strong> Dynavax Technologies 專注於新型疫苗的發現、開發和商業化，收入為 3.3051 億美元。公司在生物製藥領域運營，主要強調疫苗創新和國內外分銷。</p>
<p>在變革階段的 Dynavax Technologies 顯示出強勁的財務和運營增長，最近被賽諾菲以 19 億美元收購，表明市場信心強勁。這一戰略舉措得到了年度盈利增長 52.76% 的顯著預測和季度收入從 8063 萬美元躍升至 9488 萬美元的令人印象深刻的增長的支持。公司的創新承諾在其研發項目中顯而易見，例如 Z-1018 帶狀皰疹疫苗，與已建立的產品競爭，展示了 Dynavax 對公共健康的重大影響潛力。</p>
<ul>
<li>點擊這裏發現 Dynavax Technologies 的細微差別，查看我們的詳細分析健康報告。</li>
<li>查看我們的歷史表現報告，以獲取對 Dynavax Technologies 過去表現的洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ac20658d-f845-433c-9f57-6c7b056968ea/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ac20658d-f845-433c-9f57-6c7b056968ea/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 DVAX 收入和支出細分</p>
<h2>Phreesia (PHR)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Phreesia, Inc. 提供一個集成的基於 SaaS 的軟件和支付平台，專為美國和加拿大的醫療行業量身定製，市值約為 9.9293 億美元。</p>
<p><strong>運營：</strong> Phreesia 主要通過其技術解決方案部門產生收入，該部門佔 463.21 百萬美元。</p>
<p>Phreesia 展現了顯著的扭轉，從最近的季度報告中顯示出從淨虧損 1440 萬美元轉變為淨收入 427 萬美元，反映出顯著的運營改善和有效的成本管理。這一轉變得到了年度收入增長 10.7% 的支持，使公司在競爭激烈的科技領域中處於良好位置。進一步增強投資者信心的是，Phreesia 將其 2026 財年的收入預測提高至 4.79 億至 4.81 億美元，表明持續的增長勢頭和戰略業務擴展，例如預計將貢獻額外 750 萬美元收入的 AccessOne 整合。這種在預測和適應市場需求方面的積極做法表明 Phreesia 在高科技解決方案中的持續擴展前景良好。</p>
<ul>
<li>點擊以探索我們在 Phreesia 健康報告中的詳細發現。</li>
<li>通過我們的詳細歷史表現報告評估 Phreesia 的過去表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/966203ed-2bd1-4229-9f79-b4030f1b40d5/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/966203ed-2bd1-4229-9f79-b4030f1b40d5/chart/revenue-and-expenses-breakdown"/></p>
<p>PHR 收入和支出明細截至 2025 年 12 月</p>
<h2>讓它發生</h2>
<ul>
<li>點擊這裏深入瞭解 73 只美國高增長科技和人工智能股票的世界。</li>
<li>投資了這些股票嗎？通過 Simply Wall St 簡化您的投資組合管理，並通過我們的警報及時獲取股票的任何重要更新。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會的世界，並獲取各市場無與倫比的股票分析。</li>
</ul>
<h2>準備好不同的方法了嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>用於國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是類人機器人。它是能夠在 30 分鐘內提供 5G、ISR 和雷達的全自動塔，適用於任何地方。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

PLTR

<p>美國股市正在創下新高，科技股領漲。投資者正在關注高增長領域的機會。頂尖科技公司如 Marker Therapeutics、Palantir 和 Workday 顯示出顯著的收入和盈利增長。Viant Technology、Dynavax Technologies 和 Phreesia 因其戰略舉措和財務增長而受到關注。Viant 專注於廣告技術，Dynavax 專注於疫苗，Phreesia 專注於醫療軟件。文章鼓勵探索 73 只高增長的科技和人工智能股票，以尋找潛在的投資機會</p>

<p>As the U.S. stock market reaches new highs with the S&amp;P 500 closing at a record level and tech stocks leading recent gains, investors are closely watching high-growth sectors for potential opportunities. In this environment, identifying strong tech stocks involves considering their capacity for innovation and resilience amid evolving economic conditions.</p>
<div class="lb-trans"><p>隨着美國股市創下新高，標準普爾 500 指數收於歷史最高水平，科技股引領近期漲幅，投資者密切關注高增長行業的潛在機會。在這種環境下，識別強勁的科技股需要考慮它們在不斷變化的經濟條件下的創新能力和韌性。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美國十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>HubSpot</td>
<td>14.28%</td>
<td>48.34%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Precigen</td>
<td>55.77%</td>
<td>79.70%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.13%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.08%</td>
<td>84.58%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>HubSpot</td>
<td>14.28%</td>
<td>48.34%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Precigen</td>
<td>55.77%</td>
<td>79.70%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.70%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器的 73 只股票完整列表。</p>
</div><p>Let's dive into some prime choices out of from the screener.</p>
<div class="lb-trans"><p>讓我們深入探討篩選器中的一些優質選擇。</p>
</div><h2>Viant Technology (DSP)</h2>
<div class="lb-trans"><h2>Viant Technology (DSP)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Viant Technology Inc. is an advertising technology company with a market capitalization of approximately $741.88 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Viant Technology Inc. 是一家廣告技術公司，市值約為 7.4188 億美元。</p>
</div><p><strong>Operations:</strong> Viant Technology generates revenue primarily through its Enterprise Technology Platform, which contributed $324.13 million. The company focuses on providing advertising technology solutions to its clients.</p>
<div class="lb-trans"><p><strong>運營：</strong> Viant Technology 主要通過其企業技術平台產生收入，該平台貢獻了 3.2413 億美元。公司專注於為客户提供廣告技術解決方案。</p>
</div><p>Viant Technology's strategic moves, including a notable integration with iHeartMedia and partnerships like the one with Molson Coors, underscore its commitment to enhancing programmatic advertising and outcome-driven strategies. This is evident from its 13.3% annual revenue growth and robust earnings growth of 44.2% per year, outpacing the US market average. The company's recent third-quarter sales increase to $85.58 million from $79.92 million the previous year reflects a solid execution of its business model in a competitive tech landscape. Viant's focus on direct publisher relationships through initiatives like Direct Access further positions it as an innovator in connected TV (CTV) and digital advertising spaces, leveraging advanced technology to optimize ad spending efficiency and effectiveness.</p>
<div class="lb-trans"><p>Viant Technology 的戰略舉措，包括與 iHeartMedia 的顯著整合以及與 Molson Coors 的合作，突顯了其提升程序化廣告和結果驅動策略的承諾。這從其年收入增長 13.3% 和年盈利增長 44.2% 中可見一斑，均超過美國市場平均水平。公司最近第三季度的銷售額從去年 79.92 百萬美元增加到 85.58 百萬美元，反映出其在競爭激烈的科技領域中成功執行商業模式。Viant 通過直接訪問等舉措專注於與出版商的直接關係，進一步將其定位為連接電視（CTV）和數字廣告領域的創新者，利用先進技術優化廣告支出效率和效果。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Viant Technology.</li>
<li>Learn about Viant Technology's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 Viant Technology 的動態。</li>
<li>瞭解 Viant Technology 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d76d5b3b-65f9-42ba-b2be-d5bd08db8e8d/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/d76d5b3b-65f9-42ba-b2be-d5bd08db8e8d/chart/revenue-and-expenses-breakdown"/></p>
<p>DSP Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 DSP 收入和支出細分</p>
</div><h2>Dynavax Technologies (DVAX)</h2>
<div class="lb-trans"><h2>Dynavax Technologies (DVAX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that specializes in developing and commercializing vaccines both in the United States and internationally, with a market cap of approximately $1.31 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Dynavax Technologies Corporation 是一家商業階段的生物製藥公司，專注於在美國和國際上開發和商業化疫苗，市值約為 13.1 億美元。</p>
</div><p><strong>Operations:</strong> Dynavax Technologies focuses on the discovery, development, and commercialization of novel vaccines, generating revenue of $330.51 million. The company operates in the biopharmaceutical sector with a primary emphasis on vaccine innovation and distribution both domestically and internationally.</p>
<div class="lb-trans"><p><strong>運營：</strong> Dynavax Technologies 專注於新型疫苗的發現、開發和商業化，收入為 3.3051 億美元。公司在生物製藥領域運營，主要強調疫苗創新和國內外分銷。</p>
</div><p>Dynavax Technologies, amid a transformative phase, has shown robust financial and operational growth with its recent acquisition by Sanofi for $1.9 billion, signaling strong market confidence. This strategic move is complemented by a significant 52.76% forecast in annual earnings growth and an impressive jump in quarterly revenue from $80.63 million to $94.88 million year-over-year. The firm's commitment to innovation is evident from its R&amp;D initiatives like the Z-1018 shingles vaccine, which competes closely with established products, showcasing Dynavax's potential to impact public health significantly.</p>
<div class="lb-trans"><p>在變革階段的 Dynavax Technologies 顯示出強勁的財務和運營增長，最近被賽諾菲以 19 億美元收購，表明市場信心強勁。這一戰略舉措得到了年度盈利增長 52.76% 的顯著預測和季度收入從 8063 萬美元躍升至 9488 萬美元的令人印象深刻的增長的支持。公司的創新承諾在其研發項目中顯而易見，例如 Z-1018 帶狀皰疹疫苗，與已建立的產品競爭，展示了 Dynavax 對公共健康的重大影響潛力。</p>
</div><ul>
<li>Click here to discover the nuances of Dynavax Technologies with our detailed analytical health report.</li>
<li>Review our historical performance report to gain insights into Dynavax Technologies''s past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏發現 Dynavax Technologies 的細微差別，查看我們的詳細分析健康報告。</li>
<li>查看我們的歷史表現報告，以獲取對 Dynavax Technologies 過去表現的洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ac20658d-f845-433c-9f57-6c7b056968ea/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/ac20658d-f845-433c-9f57-6c7b056968ea/chart/revenue-and-expenses-breakdown"/></p>
<p>DVAX Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 DVAX 收入和支出細分</p>
</div><h2>Phreesia (PHR)</h2>
<div class="lb-trans"><h2>Phreesia (PHR)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Phreesia, Inc. offers an integrated SaaS-based software and payment platform tailored for the healthcare industry across the United States and Canada, with a market cap of approximately $992.93 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Phreesia, Inc. 提供一個集成的基於 SaaS 的軟件和支付平台，專為美國和加拿大的醫療行業量身定製，市值約為 9.9293 億美元。</p>
</div><p><strong>Operations:</strong> Phreesia generates revenue primarily from its Technology Solutions segment, which accounted for $463.21 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> Phreesia 主要通過其技術解決方案部門產生收入，該部門佔 463.21 百萬美元。</p>
</div><p>Phreesia has demonstrated a notable turnaround, transitioning from a net loss of $14.4 million to a net income of $4.27 million in its recent quarterly report, reflecting significant operational improvements and effective cost management. This shift is underscored by an impressive 10.7% annual revenue growth, positioning the company well within the competitive tech landscape. Further bolstering investor confidence, Phreesia has raised its fiscal 2026 revenue forecast to between $479 million and $481 million, indicative of sustained growth momentum and strategic business expansions such as the AccessOne integration expected to contribute an additional $7.5 million in revenue. This proactive approach in forecasting and adapting to market demands suggests promising prospects for Phreesia's continued expansion in high-tech solutions.</p>
<div class="lb-trans"><p>Phreesia 展現了顯著的扭轉，從最近的季度報告中顯示出從淨虧損 1440 萬美元轉變為淨收入 427 萬美元，反映出顯著的運營改善和有效的成本管理。這一轉變得到了年度收入增長 10.7% 的支持，使公司在競爭激烈的科技領域中處於良好位置。進一步增強投資者信心的是，Phreesia 將其 2026 財年的收入預測提高至 4.79 億至 4.81 億美元，表明持續的增長勢頭和戰略業務擴展，例如預計將貢獻額外 750 萬美元收入的 AccessOne 整合。這種在預測和適應市場需求方面的積極做法表明 Phreesia 在高科技解決方案中的持續擴展前景良好。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Phreesia's health report.</li>
<li>Assess Phreesia's past performance with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊以探索我們在 Phreesia 健康報告中的詳細發現。</li>
<li>通過我們的詳細歷史表現報告評估 Phreesia 的過去表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/966203ed-2bd1-4229-9f79-b4030f1b40d5/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/966203ed-2bd1-4229-9f79-b4030f1b40d5/chart/revenue-and-expenses-breakdown"/></p>
<p>PHR Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>PHR 收入和支出明細截至 2025 年 12 月</p>
</div><h2>Make It Happen</h2>
<div class="lb-trans"><h2>讓它發生</h2>
</div><ul>
<li>Gain an insight into the universe of 73 US High Growth Tech and AI Stocks by clicking here.</li>
<li>Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.</li>
<li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 73 只美國高增長科技和人工智能股票的世界。</li>
<li>投資了這些股票嗎？通過 Simply Wall St 簡化您的投資組合管理，並通過我們的警報及時獲取股票的任何重要更新。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會的世界，並獲取各市場無與倫比的股票分析。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>準備好不同的方法了嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用於國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人機器人。它是能夠在 30 分鐘內提供 5G、ISR 和雷達的全自動塔，適用於任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

Exploring US High Growth Tech Stocks for Potential Expansion

- 美股市場創下新高，S&P 500 達歷史最高位。
- 投資者關注高增長行業，以尋找潛在機會。
- 高增長科技公司的收入和盈利增長顯著，例如 Viant 和 Dynavax。

探索美國高增長科技股的擴展潛力